Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HLA-C drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HLA-C08:02, HLA-C07:02, and HLA-C*06:02 Complexes / Mutant Proteins High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View HLA-C Products |
| Gene Delivery | HLA-C Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Conformationally intact presentation. |
View HLA-C Products |
| Benchmark Ab | Anti-HLA-C Recombinant Antibody Recombinant positive control for flow cytometry and binding assays. |
View HLA-C Products |
| Validator | HLA-C siRNA Set For knockdown verification in functional assays. |
View HLA-C Products |
| Related Target A | KIR2DL1 Inhibitory NK cell receptor; interacts with HLA-C to regulate NK cell cytotoxicity. |
View KIR2DL1 Products |
| Related Target B | B2M (Beta-2 Microglobulin) Essential light chain subunit for stable HLA-C cell surface expression and folding. |
View B2M Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Allele-specific binding validation (e.g., C08:02 vs C07:02) | Polymorphic HLA-C allele variants available with sequence verification and high purity (>95%) |
| High homology cross-reactivity screening (HLA-A/B off-target) | Recombinant MHC Class I panel proteins strictly verified by mass spectrometry |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live HLA-C R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HLA-C therapeutics is intensifying, with major players shifting focus from traditional mAbs to TCR-T and NK-cell engagers. As first-generation checkpoint therapies reach the clinic, the next wave of R&D is targeting specific HLA-C-restricted neoantigens (such as KRAS G12D presented by HLA-C*08:02) and engineering HLA-C-silent hypoimmunogenic universal CAR-T/NK cells to bypass host immune rejection.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-T | Affini-T Therapeutics, Adaptimmune | Solid Tumors (KRAS G12D+) | MHC-Peptide Complex stability assays (Need sequence-verified recombinant HLA-C monomers) |
| NK Engager / Bispecific | Innate Pharma, Bristol Myers Squibb | Hematological & Solid Tumors | KIR2DL1/2/3 binding and blocking verification (Need native glycosylation proteins) |
| Gene Edited CAR-T/NK | Sana Biotechnology, CRISPR Therapeutics | Off-the-shelf Cell Therapy | HLA-C knockout validation (Need high-titer Lentivirus & validated siRNA sets) |